Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review
High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advance...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2067 |
| _version_ | 1797536418901262336 |
|---|---|
| author | Melissa Bradbury Eva Borràs Assumpció Pérez-Benavente Antonio Gil-Moreno Anna Santamaria Eduard Sabidó |
| author_facet | Melissa Bradbury Eva Borràs Assumpció Pérez-Benavente Antonio Gil-Moreno Anna Santamaria Eduard Sabidó |
| author_sort | Melissa Bradbury |
| collection | DOAJ |
| description | High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets. |
| first_indexed | 2024-03-10T11:59:27Z |
| format | Article |
| id | doaj.art-fae073f172274da4a5ebbc1668c9c502 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:59:27Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fae073f172274da4a5ebbc1668c9c5022023-11-21T17:04:15ZengMDPI AGCancers2072-66942021-04-01139206710.3390/cancers13092067Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-ReviewMelissa Bradbury0Eva Borràs1Assumpció Pérez-Benavente2Antonio Gil-Moreno3Anna Santamaria4Eduard Sabidó5Centre de Regulació Genòmica, Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, 08003 Barcelona, SpainCentre de Regulació Genòmica, Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, 08003 Barcelona, SpainBiomedical Research Group in Gynecology, Vall d’Hebron Institut de Recerca, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, SpainBiomedical Research Group in Gynecology, Vall d’Hebron Institut de Recerca, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, SpainBiomedical Research Group in Gynecology, Vall d’Hebron Institut de Recerca, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, SpainCentre de Regulació Genòmica, Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, 08003 Barcelona, SpainHigh-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.https://www.mdpi.com/2072-6694/13/9/2067ovarian cancermass spectrometryproteomicsgenomicscancer tissuebiomarker |
| spellingShingle | Melissa Bradbury Eva Borràs Assumpció Pérez-Benavente Antonio Gil-Moreno Anna Santamaria Eduard Sabidó Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review Cancers ovarian cancer mass spectrometry proteomics genomics cancer tissue biomarker |
| title | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review |
| title_full | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review |
| title_fullStr | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review |
| title_full_unstemmed | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review |
| title_short | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review |
| title_sort | proteomic studies on the management of high grade serous ovarian cancer patients a mini review |
| topic | ovarian cancer mass spectrometry proteomics genomics cancer tissue biomarker |
| url | https://www.mdpi.com/2072-6694/13/9/2067 |
| work_keys_str_mv | AT melissabradbury proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview AT evaborras proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview AT assumpcioperezbenavente proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview AT antoniogilmoreno proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview AT annasantamaria proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview AT eduardsabido proteomicstudiesonthemanagementofhighgradeserousovariancancerpatientsaminireview |